Phytopharm Share Discussion Threads

[moneymunch] 17/3/2013 22:29

GL MrsA, hope this helps...


Another failure this month has been Phytopharm's phase II compound, Cogane, in early stage Parkinson's disease. As Phytopharm does not have a portfolio of other late stage projects to develop in place of Cogane, the company is looking at "other strategic options". The most likely is a reverse merger with another company that is looking to obtain a London stock market listing. Degenerative neurological diseases is a graveyard for new molecules but perhaps more patient specific tailored treatments along the lines of the one Merck Serono has licensed from Opexa Therapeutics (described above), will be more successful.

[mrsapeslaptop] 14/3/2013 00:17

my guess is.

a) fundraising for another £5m to do a phase II trial.
Smaller than previously envisaged. learning lessons from PD trial (why spend so much money before discovering it doesnt work).

b) Charidee funding for a Phase IIa trial (the preclinical is quite good, and little alternative pipeline for the indication\0

c) Takeout c 6p. justified on a financial business case for the cash & tax losses (and the IP gained is therefore free).

d) Return to shareholders.

but I think this may 3 bag within 6 months

[mrsapeslaptop] 13/3/2013 14:10

and Biogen's ALS failure.

[mrsapeslaptop] 13/3/2013 13:44

here is the press release.



yes you are right. some financial & logistics supported by charity, dependent on PYM moving forward.

Here is the more detailed info from one of the charities involved.

[mrsapeslaptop] 13/3/2013 13:10

Gerhart.

my reading of the PII/III trial is that it was being grant funded in the US (i.e. PYM not paying for it). always still possible it wont. but we do have orphan status.

[gerhart] 13/3/2013 12:19

Thanks for setting up the new thread Mrs A - I was starting to think I was on my own.

Agree with most of the above. But the general vibes I could read were that any further trials would have to be stopped as there wasn't high degree of certainy of success. The money was to be saved as best chance of saving Co. (which has been on the market since 1996 I think - so no flakey operation).

Some cash shells i have seen recently just snowball to multibaggers, on hopes alone, over a few days. This one seems better than most. Assuming it becomes cash shell. G

[mrsapeslaptop] 13/3/2013 10:28

1. Company has had disasters in clinical trials for Alzheimers & Parkinsons in the past.

I however have added significantly at 1.7p as I believe it is undervalued.

a) valued at £5.6m which is cash at bank, and minimal cash burn
b) has £80m of tax losses. potentially worth an extra 4p a share to a profitable trading company
c) Ftse listing for a reverse takover

D) We dont know what is happening on the ALS trial. This is potentially funded and fast tracked for a PII/ III trial in the US. This may now not happen due to poor Parkinsons results. But if it does go ahead its a potential $2Bn a year market. Large gamble involved if this trila will still proceed.

Of course it may just sit here as a cash shell for years.

But Im in farly large for me at this price. DYOR

[muto] 24/2/2013 18:56

Why are you all suprised. 50/50 chance of success. You all bet on the wrong 50.

[xrougetraderx] 21/2/2013 15:21

PYMAs at 30 September 2012, the Group had cash resources of £8,887,220 which the Group considers sufficient to finance its operational activities until at least the end of Q1 2014.

[daytraders] 20/2/2013 16:03

I will defo buy if we get to a market capital of about 5mill.

[gerhart] 20/2/2013 13:12

It'll probably be regretfully, but one of the 500Ks is a buy of mine Parsons. I'm no "stake builder" but i do think despite all the negative points, this is still worth a punt because of the positives. G

[parsons] 20/2/2013 12:16

Unless the deals at 1.8505 are buys then there are so many sells and the price is staying firm. Anyway I agree with piccolino3 these are cheap for a company with a full listing and cash.

[gerhart] 20/2/2013 11:57

Why you say that Parsons?

[monkey puzzle] 20/2/2013 10:56

aqui11a,

well said and about time too, the man is like a case of thrush......

[parsons] 20/2/2013 10:50

It looks to me like stakebuilding here !!

[aqui11a] 19/2/2013 22:39

Loverat regarding your post 470.

It's rude of you coming here and start calling people fools.
You have a reputation as a bottom fisher and you have had your fingers burnt at pmk, char, fogl and ipm.

Now jog on, you idiot.

[piccolino3] 19/2/2013 21:27

Net cash of £5.5 million, accumulated tax losses in excess of £50 million, a product pipeline and a main board quotation, worth far more than 1p per share, and with two major shareholders owning 70%, far from doomed I would say!